INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2018 | $4,069,000 | +22.8% | 187,500 | 0.0% | 0.15% | +15.7% |
Q2 2018 | $3,313,000 | -16.1% | 187,500 | 0.0% | 0.13% | -24.4% |
Q1 2018 | $3,947,000 | +45.4% | 187,500 | 0.0% | 0.17% | +36.6% |
Q4 2017 | $2,715,000 | -8.2% | 187,500 | 0.0% | 0.12% | -10.2% |
Q3 2017 | $2,959,000 | +27.1% | 187,500 | 0.0% | 0.14% | +16.1% |
Q2 2017 | $2,329,000 | -24.6% | 187,500 | -1.3% | 0.12% | -33.7% |
Q1 2017 | $3,088,000 | +7.7% | 190,000 | 0.0% | 0.18% | -7.3% |
Q4 2016 | $2,867,000 | -1.0% | 190,000 | 0.0% | 0.19% | +5.5% |
Q3 2016 | $2,896,000 | -60.7% | 190,000 | 0.0% | 0.18% | -66.7% |
Q2 2016 | $7,376,000 | +41.5% | 190,000 | +1.3% | 0.55% | +24.9% |
Q1 2016 | $5,213,000 | -46.2% | 187,500 | +4.2% | 0.44% | -40.5% |
Q4 2015 | $9,682,000 | +34.3% | 180,000 | 0.0% | 0.73% | +25.5% |
Q3 2015 | $7,207,000 | – | 180,000 | – | 0.58% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |